Digital pathology for reporting histopathology samples, including cancer screening samples – definitive evidence from a multisite study

Azam, Ayesha S; Tsang, Yee‐Wah; Thirlwall, Jenny; Kimani, Peter K; Sah, Shatrughan; Gopalakrishnan, Kishore; Boyd, Clinton; Loughrey, Maurice B; Kelly, Paul J; Boyle, David P; Salto‐Tellez, Manuel; Clark, David; Ellis, Ian O; Ilyas, Mohammad; Rakha, Emad; Bickers, Adam; Roberts, Ian S D; Soares, Maria F; Neil, Desley A H; Takyi, Abi; Raveendran, Sinthuri; Hero, Emily; Evans, Harriet; Osman, Rania; Fatima, Khunsha; Hughes, Rhian W; McIntosh, Stuart A; Moran, Gordon W; Ortiz‐Fernandez‐Sordo, Jacobo; Rajpoot, Nasir M; Storey, Ben; Ahmed, Imtiaz; Dunn, Janet A; Hiller, Louise; Snead, David R J

doi:10.1111/his.15129

All Outputs (7)

ATF4 as a Prognostic Marker and Modulator of Glutamine Metabolism in Estrogen Receptor Positive Breast Cancer (2024)
Journal Article
Patel, R., Alfarsi, L. H., El-Ansari, R., Masisi, B. K., Erkan, B., Fakroun, A., …Green, A. R. (in press). ATF4 as a Prognostic Marker and Modulator of Glutamine Metabolism in Estrogen Receptor Positive Breast Cancer. Pathobiology,

Introduction: ATF4, a stress-responsive transcription factor that upregulates adaptive genes, is a potential prognostic marker and modulator of glutamine metabolism in breast cancer. However, its exact role remains to be elucidated. Methods: ATF4... Read More about ATF4 as a Prognostic Marker and Modulator of Glutamine Metabolism in Estrogen Receptor Positive Breast Cancer.

Tripartite Motif Containing 2, a glutamine metabolism-associated protein, predicts poor patient outcome in triple negative breast cancer treated with chemotherapy (2024)
Journal Article
Masisi, B. K., El Ansari, R., Alfarsi, L., Fakroun, A., Erkan, B., Ibrahim, A., …Green, A. R. (2024). Tripartite Motif Containing 2, a glutamine metabolism-associated protein, predicts poor patient outcome in triple negative breast cancer treated with chemotherapy. Cancers, 16(11), Article 1949. https://doi.org/10.3390/cancers16111949

Background Breast cancer (BC) remains heterogeneous in terms of prognosis and response to treatment. Metabolic reprogramming is a critical part of oncogenesis and a potential therapeutic target. Glutaminase (GLS), which generates glutamate from glu... Read More about Tripartite Motif Containing 2, a glutamine metabolism-associated protein, predicts poor patient outcome in triple negative breast cancer treated with chemotherapy.

Intraoperative spectroscopic evaluation of sentinel lymph nodes in breast cancer surgery (2024)
Journal Article
Barkur, S., Boitor, R. A., Mihai, R., Raja Gopal, N. S., Leeney, S., Koloydenko, A. A., …Notingher, I. (2024). Intraoperative spectroscopic evaluation of sentinel lymph nodes in breast cancer surgery. Breast Cancer Research and Treatment, https://doi.org/10.1007/s10549-024-07349-z

Background and objectives: Sentinel lymph node (SLN) biopsy is a standard procedure for patients with breast cancer and normal axilla on imaging. Positive SLNs on histological examination can lead to a subsequent surgery for axillary lymph node clear... Read More about Intraoperative spectroscopic evaluation of sentinel lymph nodes in breast cancer surgery.

Deciphering the Clinical Behaviour of Invasive Lobular Carcinoma of the Breast Defines an Aggressive Subtype (2024)
Journal Article
Makhlouf, S., Atallah, N. M., Polotto, S., Lee, A. H. S., Green, A. R., & Rakha, E. A. (2024). Deciphering the Clinical Behaviour of Invasive Lobular Carcinoma of the Breast Defines an Aggressive Subtype. Cancers, 16(10), Article 1893. https://doi.org/10.3390/cancers16101893

Background: Invasive lobular carcinoma (ILC), the most common special type of breast cancer (BC), has unique clinical behaviour and is different from invasive ductal carcinoma of no special type (IDC-NST). However, ILC further comprises a diverse gro... Read More about Deciphering the Clinical Behaviour of Invasive Lobular Carcinoma of the Breast Defines an Aggressive Subtype.

The Clinicopathological Significance of the Cyclin D1/E1–Cyclin-Dependent Kinase (CDK2/4/6)–Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers (2024)
Journal Article
Lashen, A., Algethami, M., Alqahtani, S., Shoqafi, A., Sheha, A., Jeyapalan, J. N., …Madhusudan, S. (2024). The Clinicopathological Significance of the Cyclin D1/E1–Cyclin-Dependent Kinase (CDK2/4/6)–Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers. International Journal of Molecular Sciences, 25(7), Article 4060. https://doi.org/10.3390/ijms25074060

Cyclin-dependent kinases (CDK2, CDK4, CDK6), cyclin D1, cyclin E1 and phosphorylated retinoblastoma (pRB1) are key regulators of the G1/S cell cycle checkpoint and may influence platinum response in ovarian cancers. CDK2/4/6 inhibitors are emerging t... Read More about The Clinicopathological Significance of the Cyclin D1/E1–Cyclin-Dependent Kinase (CDK2/4/6)–Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers.

The characteristics and prognostic significance of histone H1 expression in breast cancer (2024)
Journal Article
Lashen, A. G., Almalki, N., Toss, M., Mirza, S., Malki, M. I., Rutland, C. S., …Rakha, E. A. (in press). The characteristics and prognostic significance of histone H1 expression in breast cancer. Pathology,

Digital pathology for reporting histopathology samples, including cancer screening samples – definitive evidence from a multisite study (2024)
Journal Article
Azam, A. S., Tsang, Y., Thirlwall, J., Kimani, P. K., Sah, S., Gopalakrishnan, K., …Snead, D. R. J. (2024). Digital pathology for reporting histopathology samples, including cancer screening samples – definitive evidence from a multisite study. Histopathology, 84(5), 847-862. https://doi.org/10.1111/his.15129

Aims: To conduct a definitive multicentre comparison of digital pathology (DP) with light microscopy (LM) for reporting histopathology slides including breast and bowel cancer screening samples. Methods: A total of 2024 cases (608 breast, 607 GI, 6... Read More about Digital pathology for reporting histopathology samples, including cancer screening samples – definitive evidence from a multisite study.